Vancomycin-resistant enterococcus bloodstream infection successfully managed with oritavancin and fosfomycin as sequential treatment
J Chemother. 2023 Aug 21:1-4. doi: 10.1080/1120009X.2023.2247205. Online ahead of print.ABSTRACTBloodstream infections caused by vancomycin-resistant enterococci are increasingly reported and a consensus therapy does not exist. Oritavancin has shown good antimicrobial activity against VRE, but its use is mainly limited to skin, soft tissue, and/or bone infections. Fosfomycin is increasingly used for enterococcal infections (including bloodstream infections and endocarditis) as a partner drug given its anti-biofilm and synergistic properties. Recently in vitro and in vivo synergism between oritavancin and fosfomycin against...
Source: Journal of Chemotherapy - August 21, 2023 Category: Cancer & Oncology Authors: Caterina Di Cecco Jacopo Monticelli Stefano Di Bella Vittorio Di Maso Roberto Luzzati Source Type: research
Combined impact of hypoalbuminemia and pharmacogenomic variants on voriconazole trough concentration: data from a real-life clinical setting in the Chinese population
J Chemother. 2023 Aug 20:1-11. doi: 10.1080/1120009X.2023.2247208. Online ahead of print.ABSTRACTVoriconazole (VRC) displays highly variable pharmacokinetics impacting treatment efficacy and safety. To provide evidence for optimizing VRC therapy regimens, the authors set out to determine the factors impacting VRC steady-state trough concentration (Cmin) in patients with various albumin (Alb) level. A total of 275 blood samples of 120 patients and their clinical characteristics and genotypes of CYP2C19, CYP3A4, CYP3A5, CYP2C9, FMO3, ABCB1, POR, NR1I2 and NR1I3 were included in this study. Results of multivariate linear regr...
Source: Journal of Chemotherapy - August 21, 2023 Category: Cancer & Oncology Authors: Yuanyuan Li Ying Zhang Jinxia Zhao Jialu Bian Yinyu Zhao Xu Hao Boyu Liu Lei Hu Fang Liu Changqing Yang Yufei Feng Lin Huang Source Type: research
Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer
J Chemother. 2023 Aug 20:1-9. doi: 10.1080/1120009X.2023.2247207. Online ahead of print.ABSTRACTTo evaluate the tumour-infiltrating lymphocyte (TIL) rates in breast tissue before and after neoadjuvant chemotherapy (NAC) and their impact on survival, eighty-four patients with locally advanced breast cancer (LABC) were assessed. Pre- and post-NAC TIL levels were determined using biopsy and surgical specimens, respectively. The median TIL rate was significantly different before (17.5%) and after (5%) NAC. Pre- and postoperative Ki-67 index, molecular subtype, pre- and post-NAC TIL concentration, and preoperative residual-canc...
Source: Journal of Chemotherapy - August 21, 2023 Category: Cancer & Oncology Authors: Vedat Bugra Erol Sabin Goktas Aydin Ahmet Bilici Asli Cakir Ozgur Acikgoz Omer Fatih Olmez Pelin Basim Source Type: research
Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and < em > IDH1/2 < /em > mutation: a network meta-analysis
In conclusion, venetoclax plus azacitidine could be a good option for unfit newly diagnosed patients with acute myeloid leukemia and IDH1/2 mutation. Considering our limits (only trial data-based network meta-analysis et al.), future trials directly comparing these regimens are warranted.PMID:37599456 | DOI:10.1080/1120009X.2023.2247200 (Source: Journal of Chemotherapy)
Source: Journal of Chemotherapy - August 21, 2023 Category: Cancer & Oncology Authors: Lida Wang Jiwu Song Xiangming Xiao Dianfang Li Tianmeng Liu Xiaopo He Source Type: research
Vancomycin-resistant enterococcus bloodstream infection successfully managed with oritavancin and fosfomycin as sequential treatment
J Chemother. 2023 Aug 21:1-4. doi: 10.1080/1120009X.2023.2247205. Online ahead of print.ABSTRACTBloodstream infections caused by vancomycin-resistant enterococci are increasingly reported and a consensus therapy does not exist. Oritavancin has shown good antimicrobial activity against VRE, but its use is mainly limited to skin, soft tissue, and/or bone infections. Fosfomycin is increasingly used for enterococcal infections (including bloodstream infections and endocarditis) as a partner drug given its anti-biofilm and synergistic properties. Recently in vitro and in vivo synergism between oritavancin and fosfomycin against...
Source: Journal of Chemotherapy - August 21, 2023 Category: Cancer & Oncology Authors: Caterina Di Cecco Jacopo Monticelli Stefano Di Bella Vittorio Di Maso Roberto Luzzati Source Type: research
PD-1 inhibitors plus chemotherapy as first-line therapy for stage IV ESCC
In this study, fifty patients (n = 25 each group) were included, all of whom could be evaluated for efficacy. PD-1 inhibitors plus chemotherapy exhibited better OS than chemotherapy alone (median 15.8 vs 12.4 months, hazard ratio [HR] 0.46 [95% CI 0.23-0.95]; P = 0.036). The median PFS for the PD-1 inhibitors plus chemotherapy group was 8.7 months compared with 6.1 months for the chemotherapy group (HR 0.48 [95% CI 0.26-0.90]; P = 0.014). Adverse events (AEs) of grade 3 or above related to treatment were found in 24.0% and 32.0% of the PD-1 inhibitors plus chemotherapy and chemotherapy alone groups, respectively. PD-1 inhi...
Source: Journal of Chemotherapy - August 18, 2023 Category: Cancer & Oncology Authors: Jiaying Lu Zhaohui Qin Ji Ma Nan Yao Wanxi Qu Li Cui Shiwang Yuan Yuanhu Yao Source Type: research
Oxaliplatin ‑induced changes in splenic volume and liver fibrosis indices: retrospective analyses of colon cancer patients receiving adjuvant chemotherapy
J Chemother. 2023 Aug 14:1-9. doi: 10.1080/1120009X.2023.2246786. Online ahead of print.ABSTRACTThe aim of our study was to evaluate the association between increased splenic volume (SV) and liver fibrosis indices in colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Patients who received adjuvant oxaliplatin-based regimens with the diagnosis of stage II and III colon cancer were evaluated. Splenic volume measurements, liver function tests, platelet count, and non-invasive liver fibrosis indices [NAFLD fibrosis score (NFS), AST to platelet ratio (APRI), and Fibrosis-4 (FIB-4)] were measured before and...
Source: Journal of Chemotherapy - August 14, 2023 Category: Cancer & Oncology Authors: Kadriye Bir Y ücel Atiye Cenay Karab örk Kilic Osman S ütcüoglu Ozan Yaz ıcı Koray Kilic G özde Savaş Aytug Uner Nazan G ünel Ahmet Özet Nuriye Özdemir Source Type: research
Dual targeting Bcl-2 and Bcl-xL augments osteosarcoma response to doxorubicin
In this study, we discovered that navitoclax, a selective inhibitor of Bcl-2/Bcl-xL, effectively combats chemoresistance in osteosarcoma. Our research revealed that Bcl-2, but not Bcl-xL, is upregulated in osteosarcoma cells that are resistant to doxorubicin. However, venetoclax, a specific inhibitor of Bcl-2, did not exhibit activity against doxorubicin-resistant cells. Further analysis showed that depleting either Bcl-2 or Bcl-xL alone was insufficient to overcome doxorubicin resistance. Only by depleting both Bcl-2 and Bcl-xL significantly reduce the viability of doxorubicin-resistant cells. Similarly, navitoclax not on...
Source: Journal of Chemotherapy - June 13, 2023 Category: Cancer & Oncology Authors: Chuanhua Cao Yu Pei Haiying Yu Huixiong Qi Source Type: research
